Download pdf
Long Noncoding RNA LINC02487 in the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells
- 1 High School Affiliated to Renmin University of China, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and a leading cause of cancer-related mortality in women. The incidence of TNBC is particularly high in China, yet treatment options remain limited, with chemotherapy—often associated with severe side effects—being the primary therapeutic approach. This study investigates the role of LINC02487 in TNBC through in vitro experiments to assess its potential as a biomolecular marker for TNBC treatment. RT-qPCR analysis revealed that LINC02487 expression was significantly upregulated in TNBC. Lentiviral transfection was used to establish LINC02487 overexpression cell lines. CCK-8 assays and EdU staining demonstrated that LINC02487 overexpression promoted TNBC cell proliferation at 24, 48, and 72 hours. Conversely, knockdown of LINC02487 inhibited TNBC cell proliferation, as confirmed by experiments using LINC02487 knockdown cell lines. Furthermore, Transwell assays indicated that LINC02487 knockdown suppressed TNBC cell migration and invasion. Overall, this study confirms the high expression of LINC02487 in TNBC and demonstrates that its knockdown can inhibit cell proliferation and metastasis, thereby slowing TNBC progression. These findings suggest that LINC02487 has potential as a novel prognostic marker and therapeutic target for TNBC, offering new hope for improved patient outcomes.
Keywords
TNBC, LINC02487, noncoding RNA, biomarker, metastasis
[1]. S. Loibl, P. Poortmans, M. Morrow, C. Denkert, and G. Curigliano, "Breast cancer," , Lancet (London, England), vol. 397, no. 10286, pp. 1750-1769, May 8 2021, doi: 10.1016/s0140-6736(20)32381-3.
[2]. M. Arnedos, C. Bihan, S. Delaloge, and F. Andre, "Triple-negative breast cancer: are we making headway at least?", Therapeutic advances in medical oncology, vol. 4, no. 4, pp. 195-210, Jul 2012, doi: 10.1177/1758834012444711.
[3]. A. M. Brewster, M. Chavez-MacGregor, and P. Brown, "Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry," , The Lancet. Oncology, vol. 15, no. 13, pp. e625-e634, Dec 2014, doi: 10.1016/s1470-2045(14)70364-x.
[4]. X. Bai, J. Ni, J. Beretov, P. Graham, and Y. Li, "Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?," , Cancer letters, vol. 497, pp. 100-111, Jan 28 2021, doi: 10.1016/j.canlet.2020.10.016.
[5]. A. K. Mehta et al., "Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer," , Nature cancer, vol. 2, no. 1, pp. 66-82, Jan 2021, doi: 10.1038/s43018-020-00148-7.
[6]. Y. Lin, J. Xu, and H. Lan, "Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications," , Journal of hematology & oncology, vol. 12, no. 1, p. 76, Jul 12 2019, doi: 10.1186/s13045-019-0760-3.
[7]. Z. Meng, R. Zhang, X. Wu, M. Zhang, and T. Jin, "PD‑L1 mediates triple‑negative breast cancer evolution via the regulation of TAM/M2 polarization," , International journal of oncology, vol. 61, no. 6, Dec 2022, doi: 10.3892/ijo.2022.5440.
[8]. I. J. Fidler and G. Poste, "The "seed and soil" hypothesis revisited," , The Lancet. Oncology, vol. 9, no. 8, p. 808, Aug 2008, doi: 10.1016/s1470-2045(08)70201-8.
[9]. Y. Lv, X. Ma, Y. Du, and J. Feng, "Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets," , OncoTargets and therapy, vol. 14, pp. 589-607, 2021, doi: 10.2147/ott.s293685.
[10]. J. Sukumar, K. Gast, D. Quiroga, M. Lustberg, and N. Williams, "Triple-negative breast cancer: promising prognostic biomarkers currently in development," , Expert review of anticancer therapy, vol. 21, no. 2, pp. 135-148, Feb 2021, doi: 10.1080/14737140.2021.1840984.
[11]. J. K. Aronson and R. E. Ferner, "Biomarkers-A General Review," , Current protocols in pharmacology, vol. 76, pp. 9.23.1-9.23.17, Mar 17 2017, doi: 10.1002/cpph.19.
[12]. Y. Shen, B. Zhang, X. Wei, X. Guan, and W. Zhang, "CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration," , International immunopharmacology, vol. 103, p. 108454, Feb 2022, doi: 10.1016/j.intimp.2021.108454.
[13]. M. J. Magbanua et al., "Circulating tumor cell analysis in metastatic triple-negative breast cancers," , Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 21, no. 5, pp. 1098-105, Mar 1 2015, doi: 10.1158/1078-0432.ccr-14-1948.
[14]. F. C. Bidard, C. Proudhon, and J. Y. Pierga, "Circulating tumor cells in breast cancer," , Molecular oncology, vol. 10, no. 3, pp. 418-30, Mar 2016, doi: 10.1016/j.molonc.2016.01.001.
[15]. C. Riebensahm et al., "Clonality of circulating tumor cells in breast cancer brain metastasis patients," , Breast cancer research : BCR, vol. 21, no. 1, p. 101, Sep 3 2019, doi: 10.1186/s13058-019-1184-2.
[16]. H. Yan and P. Bu, "Non-coding RNA in cancer," , Essays in biochemistry, vol. 65, no. 4, pp. 625-639, Oct 27 2021, doi: 10.1042/ebc20200032.
[17]. M. C. Bridges, A. C. Daulagala, and A. Kourtidis, "LNCcation: lncRNA localization and function," , The Journal of cell biology, vol. 220, no. 2, Feb 1 2021, doi: 10.1083/jcb.202009045.
[18]. M. Hill and N. Tran, "miRNA interplay: mechanisms and consequences in cancer," , Disease models & mechanisms, vol. 14, no. 4, Apr 1 2021, doi: 10.1242/dmm.047662.
[19]. M. Cesana et al., "A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA," , Cell, vol. 147, no. 2, pp. 358-69, Oct 14 2011, doi: 10.1016/j.cell.2011.09.028.
[20]. S. J. Liu, H. X. Dang, D. A. Lim, F. Y. Feng, and C. A. Maher, "Long noncoding RNAs in cancer metastasis," , Nature reviews. Cancer, vol. 21, no. 7, pp. 446-460, Jul 2021, doi: 10.1038/s41568-021-00353-1.
[21]. P. S. Wang et al., "A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer," , Oncogene, vol. 37, no. 34, pp. 4662-4678, Aug 2018, doi: 10.1038/s41388-018-0293-1.
[22]. Y. He et al., "LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer," , Gene, vol. 860, p. 147227, Apr 15 2023, doi: 10.1016/j.gene.2023.147227.
[23]. X. Liu et al., "Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis," , Cancer letters, vol. 543, p. 215781, Sep 1 2022, doi: 10.1016/j.canlet.2022.215781.
[24]. X. Liu et al., "Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis," , Cancer letters, vol. 543, p. 215781, Sep 1 2022, doi: 10.1016/j.canlet.2022.215781.
[25]. Y. L. Chen et al., "Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing," , Clinica chimica acta; international journal of clinical chemistry, vol. 531, pp. 302-308, Jun 1 2022, doi: 10.1016/j.cca.2022.04.990.
[26]. J. Kozłowska et al., "Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor," , Cancers, vol. 13, no. 12, Jun 12 2021, doi: 10.3390/cancers13122949.
[27]. Y. Li, X. Cao, and H. Li, "Identification and Validation of Novel Long Non-coding RNA Biomarkers for Early Diagnosis of Oral Squamous Cell Carcinoma," , Frontiers in bioengineering and biotechnology, vol. 8, p. 256, 2020, doi: 10.3389/fbioe.2020.00256.
[28]. L. Feng, J. Zhang, M. Sun, F. Qiu, W. Chen, and W. Qiu, "Tumor Suppressor LINC02487 Inhibits Oral Squamous Cell Carcinoma Cell Migration and Invasion Through the USP17-SNAI1 Axis," , Frontiers in oncology, vol. 10, p. 559808, 2020, doi: 10.3389/fonc.2020.559808.
[29]. S. R. Volovat et al., "MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review," , Frontiers in oncology, vol. 10, p. 526850, 2020, doi: 10.3389/fonc.2020.526850.
[30]. J. S. Mattick et al., "Long non-coding RNAs: definitions, functions, challenges and recommendations," , Nature reviews. Molecular cell biology, vol. 24, no. 6, pp. 430-447, Jun 2023, doi: 10.1038/s41580-022-00566-8.
[31]. X. Yu et al., "Promotion effect of FOXCUT as a microRNA sponge for miR-24-3p on progression in triple-negative breast cancer through the p38 MAPK signaling pathway," , Chinese medical journal, vol. 137, no. 1, pp. 105-114, Jan 5 2024, doi: 10.1097/cm9.0000000000002700.
[32]. R. Sun, S. L. He, H. Y. Liu, X. W. Wang, and S. H. Li, "Tumor Suppressor LINC02487 Inhibits the Progression of Cervical Cancer in Vitro by Regulating the PTEN/Akt/mTOR Pathway," , Discovery medicine, vol. 36, no. 187, pp. 1732-1742, Aug 2024, doi: 10.24976/Discov.Med.202436187.159.
[33]. P. Liu, W. Li, Y. Hu, and Y. Jiang, "Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer," , OncoTargets and therapy, vol. 11, pp. 5485-5498, 2018, doi: 10.2147/ott.s165874.
[34]. S. Wang et al., "Gene expression in triple-negative breast cancer in relation to survival," , Breast cancer research and treatment, vol. 171, no. 1, pp. 199-207, Aug 2018, doi: 10.1007/s10549-018-4816-9.
[35]. T. Ye et al., "LncRNA MIAT Services as a Noninvasive Biomarker for Diagnosis and Correlated with Immune Infiltrates in Breast Cancer," , International journal of women's health, vol. 13, pp. 991-1004, 2021, doi: 10.2147/ijwh.s312714.
Cite this article
Guo,Y. (2025). Long Noncoding RNA LINC02487 in the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells. Theoretical and Natural Science,99,70-84.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).